Intravascular large B-cell lymphoma (IVLBCL) is a rare type of non-Hodgkin’s lymphoma. Its symptoms can vary, making it difficult to diagnose. The outlook for people with IVLBCL is typically poor.

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...